Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to <17 Years Undergoing MRI Scans

NCT ID: NCT04237792

Last Updated: 2022-11-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

128 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-18

Study Completion Date

2021-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, dose-ranging study of the efficacy and safety of dexmedetomidine (DEX) when used with propofol as needed, for procedural sedation of pediatric subjects ≥1 month to \<17 years of age undergoing MRI scans in the US and Japan.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

MRI Sedation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dexmedetomidine low dose group

low dose of dexmedetomidine to be given

Group Type EXPERIMENTAL

dexmedetomidine

Intervention Type DRUG

dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan

propofol

Intervention Type DRUG

propofol IV administration will be given if needed to maintain sedation

dexmedetomidine middle dose group

middle dose of dexmedetomidine to be given

Group Type EXPERIMENTAL

dexmedetomidine

Intervention Type DRUG

dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan

propofol

Intervention Type DRUG

propofol IV administration will be given if needed to maintain sedation

dexmedetomidine high dose group

high dose of dexmedetomidine to be given

Group Type EXPERIMENTAL

dexmedetomidine

Intervention Type DRUG

dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan

propofol

Intervention Type DRUG

propofol IV administration will be given if needed to maintain sedation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dexmedetomidine

dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan

Intervention Type DRUG

propofol

propofol IV administration will be given if needed to maintain sedation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subject ≥1 month and \<17 years of age.
2. American Society of Anesthesiologists (ASA) Physical Status I, II or III.
3. Requires non-intubated, spontaneous breathing, moderate to deep sedation (NI MDS) for a magnetic resonance imaging (MRI) study with an intensivist, anesthesiologist or other proceduralist in attendance.
4. Duration of the MRI scan is expected to take at least 20 minutes but no more than 3 hours to complete

Exclusion Criteria

1. Pregnant female subjects (including those with an indeterminate or positive pregnancy test); breastfeeding female subjects.
2. Weight on Day 1 before randomization is less than the 10th percentile of weight for age and sex in the US and Japan or is greater than the 95th percentile of weight for age and sex in the US or greater than the 97th percentile of weight for age and sex in Japan based on sponsor-provided growth charts.
3. Planned medical procedure during the MRI scan or post-MRI recovery period.
4. Requires endotracheal intubation or laryngeal mask airway (LMA).
5. Known allergy to eggs, egg products, soybeans or soybean products.
6. SpO2 \<93 % on room air -
Minimum Eligible Age

1 Month

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arkansas Children's

Little Rock, Arkansas, United States

Site Status

Lucile Packard Children's Hospital, Stanford

Palo Alto, California, United States

Site Status

University of California Davis Medical Center

Sacramento, California, United States

Site Status

Baptist Health - Wolfson Children's Hospital

Jacksonville, Florida, United States

Site Status

St. Mary's Medical Center

West Palm Beach, Florida, United States

Site Status

Children's Healthcare of Atlanta-Egleston

Atlanta, Georgia, United States

Site Status

IU Health Riley Hospital for Children

Indianapolis, Indiana, United States

Site Status

University of Michigan, C.S. Mott Children's Hospital

Ann Arbor, Michigan, United States

Site Status

M Health Fairview University of Minnesota Medical Center - West Bank

Minneapolis, Minnesota, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

Brody School of Medicine at East Carolina University

Greenville, North Carolina, United States

Site Status

Vidant Medical Center

Greenville, North Carolina, United States

Site Status

University Hospitals Rainbow Babies and Children's Hospital

Cleveland, Ohio, United States

Site Status

The Children's Hospital at OUMC

Oklahoma City, Oklahoma, United States

Site Status

Children's Medical Center

Dallas, Texas, United States

Site Status

Texas Children's Hospital

Houston, Texas, United States

Site Status

Ibaraki Children Hospital

Mito, Ibaraki, Japan

Site Status

Shikoku Medical Center for Children and Adults

Zentsujichó, Kagawa-ken, Japan

Site Status

Osaka Women's and Children's Hospital

Izumi-shi, Osaka, Japan

Site Status

Shizuoka Children's Hospital

Shizuoka, Shizuoka, Japan

Site Status

Tokyo Metropolitan Children's Medical Center

Fuchū, Tokyo, Japan

Site Status

National Center for Child Health and Development

Setagaya-ku, Tokyo, Japan

Site Status

Osaka City General Hospital

Osaka, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Japan

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://pmiform.com/clinical-trial-info-request?StudyID=C0801039

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C0801039

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dexmedetomidine and Ketamine in MRI
NCT02652507 COMPLETED PHASE1